BackgroundThere is overlap between symptoms of perimenopause/menopause and Post-COVID syndrome and there is concern that some female patients referred to Post-COVID syndrome clinics may have undiagnosed perimenopause/menopause. However, the prevalence of such symptoms in this population is unknown. MethodsCross-sectional analysis of 122 women's health questionnaires as part of a service improvement project in 3 National Health Service (NHS) Post-COVID syndrome clinics in England. The primary outcomes were prevalence of menopause symptoms and association between total MSQ score and key predictors. ResultsAge group 40-54 showed the highest prevalence of most individual symptoms and the highest mean total MSQ score (36.4; CIs 32.3-40.6) correlating clinically with the onset of perimenopause/menopause. Regression modelling shows a significant positive parabolic relationship between age and total MSQ score. Age group 40-54 is associated with 6.60 points higher (CIs 1.31 to 11.9) total MSQ score than age group 55-79; an increase of 1 IMD quintile is associated with 2.85 points lower (CIs -1.24 to -4.45) total MSQ score; presence of a gynaecological diagnosis is associated with 6.31 points higher (CIs 1.32 to 11.3) total MSQ score. Fifty-one percent of patients who menstruate report menstrual disturbance with COVID-19 infection, and 21% with COVID-19 vaccination. ConclusionsSymptoms possibly attributable to perimenopause and menopause are highly prevalent amongst female patients attending Post-COVID syndrome clinics in Greater Manchester, England. Our findings provide key prevalence estimates and significant predictors of MSQ scores – vital for future research, clinical practice, and policy.